Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas J Moore

Showing results (11-20 of 75) with videos related to

Pageof 8
Sort By:
JAMA Internal Medicine|October 30, 2013
Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008Thomas J Moore, Curt D Furberg
Seminars in Thrombosis and Hemostasis|October 23, 2012
Underreporting of hemorrhagic and thrombotic complications of pharmaceuticals to the U.S. Food and Drug Administration: empirical findings for warfarin, clopidogrel, ticlopidine, and thalidomide from the Southern Network on Adverse Reactions (SONAR)Thomas J Moore, Charles L Bennett
JAMA Internal Medicine|December 13, 2016
Adult Utilization of Psychiatric Drugs and Differences by Sex, Age, and RaceThomas J Moore, Donald R Mattison
JAMA|September 6, 2012
The safety risks of innovation: the FDA's Expedited Drug Development PathwayThomas J Moore, Curt D Furberg
Plos One|December 24, 2010
Prescription drugs associated with reports of violence towards othersThomas J Moore, Joseph Glenmullen, Curt D Furberg
The Annals of Pharmacotherapy|July 22, 2010
Thoughts and acts of aggression/violence toward others reported in association with vareniclineThomas J Moore, Joseph Glenmullen, Curt D Furberg
Clinical Trials (London, England)|March 30, 2019
Globalization of clinical trials: Variation in estimated regional costs of pivotal trials, 2015-2016Yao Qiao, G Caleb Alexander, Thomas J Moore
Archives of Internal Medicine|January 11, 2012
The FDA and new safety warningsThomas J Moore, Sonal Singh, Curt D Furberg
The New England Journal of Medicine|December 14, 2017
The Fate of FDA Postapproval StudiesLisa M Schwartz, Steven Woloshin, Thomas J Moore
Pharmacotherapy|October 22, 2025
Developing New Drugs for the COVID-19 Emergency: Anatomy of the U.S. ResponseThomas J Moore, Mariana P Socal, Gerard Anderson
Pageof 8

Showing results (11-20 of 75) with videos related to

Sort By:
Pageof 8
JAMA Internal Medicine|October 30, 2013
Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008Thomas J Moore, Curt D Furberg
Seminars in Thrombosis and Hemostasis|October 23, 2012
Underreporting of hemorrhagic and thrombotic complications of pharmaceuticals to the U.S. Food and Drug Administration: empirical findings for warfarin, clopidogrel, ticlopidine, and thalidomide from the Southern Network on Adverse Reactions (SONAR)Thomas J Moore, Charles L Bennett
JAMA Internal Medicine|December 13, 2016
Adult Utilization of Psychiatric Drugs and Differences by Sex, Age, and RaceThomas J Moore, Donald R Mattison
JAMA|September 6, 2012
The safety risks of innovation: the FDA's Expedited Drug Development PathwayThomas J Moore, Curt D Furberg
Plos One|December 24, 2010
Prescription drugs associated with reports of violence towards othersThomas J Moore, Joseph Glenmullen, Curt D Furberg
The Annals of Pharmacotherapy|July 22, 2010
Thoughts and acts of aggression/violence toward others reported in association with vareniclineThomas J Moore, Joseph Glenmullen, Curt D Furberg
Clinical Trials (London, England)|March 30, 2019
Globalization of clinical trials: Variation in estimated regional costs of pivotal trials, 2015-2016Yao Qiao, G Caleb Alexander, Thomas J Moore
Archives of Internal Medicine|January 11, 2012
The FDA and new safety warningsThomas J Moore, Sonal Singh, Curt D Furberg
The New England Journal of Medicine|December 14, 2017
The Fate of FDA Postapproval StudiesLisa M Schwartz, Steven Woloshin, Thomas J Moore
Pharmacotherapy|October 22, 2025
Developing New Drugs for the COVID-19 Emergency: Anatomy of the U.S. ResponseThomas J Moore, Mariana P Socal, Gerard Anderson
Pageof 8